Axoltis Pharma

Let's meet Luca Bolliger (Axoltis Pharma CBO) at #BioEurope 30th Annual International Partnering Conference ! Axoltis Pharma is developing an innovative drug for CNS diseases. #NX210c, with a good safety profile, can be a breakthrough therapy for neurodegenerative diseases, restoring the impaired blood-brain barrier integrity. After a positive phase 1b clinical trial, Axoltis is launching a phase 2 in Amyotrophic Lateral Sclerosis patients.  We are looking for Pharma partners and/or investors to accelerate ! #NX210c #SLA #partnership

📯 Axoltis Pharma's team is very proud to be among the #PrixGalien USA Award nominees for "Best Startup" !   This year marks the tenth anniversary of The Galien Foundation and Business France recognizing global innovators in the "Best Startup" category. This partnership supports global healthcare startups by offering visibility on the American stage and connecting them with major players in the industry in the U.S. and Canada. Axoltis aims to expand its current panel of collaborations with academic labs and with potential pharma partners in the world, especially in North America to explore the broad range of indications of its patented lead product #NX210c.   NX210c could change the game in the treatment of neurodegenerative diseases. Aside to a neuroprotective effect, its main property is the recovery of the blood brain barrier integrity which is impaired in a broad range of diseases. Axoltis has just launched a phase II clinical trial in Amyotrophic Lateral Sclerosis (#ALS), where the #BBB is impaired since the early stages of the disease. ALS is a fatal disease with a huge unmet medical need.. #PrixGalienUSA #BusinessFranceNorthAmerica #FrenchHealthcare #ChooseFrance

Axoltis Pharma a le plaisir d'annoncer que SEALS, un essai clinique de phase 2 évaluant l’essai de NX210c chez les patients atteints de sclérose latérale amyotrophique (SLA), est lancé en France !   Axoltis Pharma is pleased to announce SEALS, a phase 2 clinical trial to evaluate NX210c in patients with Amyotrophic Lateral Sclerosis (ALS) is NOW LAUNCHED in France! The coordinating investigator is Dr Emilien Bernard, Hopital Neurologique Pierre Wertheimer - Hospices Civils de Lyon - France. 15 additional investigation sites are expected to participate. For more information about SEALS: NCT06365216 https://lc.cx/iTpyu- For more information about NX210c: https://lnkd.in/e9S6sRWm We thanks a lot #ARSLA and #ACT4ALSMND network for their help and support. Part of the study is supported by Région Auvergne-Rhône-Alpes and the French Government through i-Demo régionalisé, a France 2030 grant. #NX210c #ALS #SLA #BBB #ARSLA #ACT4ALSMND

Axoltis Pharma a le plaisir d'annoncer que SEALS, un essai clinique de phase 2 évaluant l’essai de NX210c chez les patients atteints de sclérose latérale amyotrophique (SLA), est lancé en France !   Axoltis Pharma is pleased to announce SEALS, a phase 2 clinical trial to evaluate NX210c in patients with Amyotrophic Lateral Sclerosis (ALS) is NOW LAUNCHED in France! The coordinating investigator is Dr Emilien Bernard, Hopital Neurologique Pierre Wertheimer - Hospices Civils de Lyon - France. 15 additional investigation sites are expected to participate. For more information about SEALS: NCT06365216 https://lc.cx/iTpyu- For more information about NX210c: https://lnkd.in/e9S6sRWm We thanks a lot #ARSLA and #ACT4ALSMND network for their help and support. Part of the study is supported by Région Auvergne-Rhône-Alpes and the French Government through i-Demo régionalisé, a France 2030 grant. #NX210c #ALS #SLA #BBB #ARSLA #ACT4ALSMND

Axoltis Pharma a le plaisir d'annoncer que SEALS, un essai clinique de phase 2 évaluant l’essai de NX210c chez les patients atteints de sclérose latérale amyotrophique (SLA), est lancé en France !   Axoltis Pharma is pleased to announce SEALS, a phase 2 clinical trial to evaluate NX210c in patients with Amyotrophic Lateral Sclerosis (ALS) is NOW LAUNCHED in France! The coordinating investigator is Dr Emilien Bernard, Hopital Neurologique Pierre Wertheimer - Hospices Civils de Lyon - France. 15 additional investigation sites are expected to participate. For more information about SEALS: NCT06365216 https://lc.cx/iTpyu- For more information about NX210c: https://lnkd.in/e9S6sRWm We thanks a lot #ARSLA and #ACT4ALSMND network for their help and support. Part of the study is supported by Région Auvergne-Rhône-Alpes and the French Government through i-Demo régionalisé, a France 2030 grant. #NX210c #ALS #SLA #BBB #ARSLA #ACT4ALSMND

📯 Axoltis Pharma's team is very proud to be among the #PrixGalien USA Award nominees for "Best Startup" !   This year marks the tenth anniversary of The Galien Foundation and Business France recognizing global innovators in the "Best Startup" category. This partnership supports global healthcare startups by offering visibility on the American stage and connecting them with major players in the industry in the U.S. and Canada. Axoltis aims to expand its current panel of collaborations with academic labs and with potential pharma partners in the world, especially in North America to explore the broad range of indications of its patented lead product #NX210c.   NX210c could change the game in the treatment of neurodegenerative diseases. Aside to a neuroprotective effect, its main property is the recovery of the blood brain barrier integrity which is impaired in a broad range of diseases. Axoltis has just launched a phase II clinical trial in Amyotrophic Lateral Sclerosis (#ALS), where the #BBB is impaired since the early stages of the disease. ALS is a fatal disease with a huge unmet medical need.. #PrixGalienUSA #BusinessFranceNorthAmerica #FrenchHealthcare #ChooseFrance

Axoltis Pharma is pleased to announce the European Medicines Agency (EMA) granted NX210c Orphan Drug Designation (ODD) for Amyotrophic Lateral Sclerosis (ALS) !   US FDA (USA Food and Drug Administration) already granted NX210c ODD for ALS.   In ALS the blood brain barrier is impaired even at early stage of the disease, and is related to its progression. Among its properties, NX210c is a very promising drug candidate with a neuroprotective effect and able to restore the blood brain barrier integrity. This could be a breakthrough in the treatment of ALS and more broadly of neurodegenerative diseases.   ODD is dedicated to medicines treating rare, life-threatening, or chronically debilitating diseases. The status offers key benefits including market exclusivity, clinical protocol assistance, waivers or reductions in regulatory fees. ALS was identified in 1869 by French neurologist Dr Jean-Martin Charcot. Today with about 500,000 patients worldwide with a high unmet medical need.   #NX210c #ODD #ALS #EMA #FDA #BBB Axoltis Pharma

Axoltis Pharma is pleased to announce the European Medicines Agency (EMA) granted NX210c Orphan Drug Designation (ODD) for Amyotrophic Lateral Sclerosis (ALS) !   US FDA (USA Food and Drug Administration) already granted NX210c ODD for ALS.   In ALS the blood brain barrier is impaired even at early stage of the disease, and is related to its progression. Among its properties, NX210c is a very promising drug candidate with a neuroprotective effect and able to restore the blood brain barrier integrity. This could be a breakthrough in the treatment of ALS and more broadly of neurodegenerative diseases.   ODD is dedicated to medicines treating rare, life-threatening, or chronically debilitating diseases. The status offers key benefits including market exclusivity, clinical protocol assistance, waivers or reductions in regulatory fees. ALS was identified in 1869 by French neurologist Dr Jean-Martin Charcot. Today with about 500,000 patients worldwide with a high unmet medical need.   #NX210c #ODD #ALS #EMA #FDA #BBB Axoltis Pharma

Axoltis Pharma is pleased to announce the European Medicines Agency (EMA) granted NX210c Orphan Drug Designation (ODD) for Amyotrophic Lateral Sclerosis (ALS) !   US FDA (USA Food and Drug Administration) already granted NX210c ODD for ALS.   In ALS the blood brain barrier is impaired even at early stage of the disease, and is related to its progression. Among its properties, NX210c is a very promising drug candidate with a neuroprotective effect and able to restore the blood brain barrier integrity. This could be a breakthrough in the treatment of ALS and more broadly of neurodegenerative diseases.   ODD is dedicated to medicines treating rare, life-threatening, or chronically debilitating diseases. The status offers key benefits including market exclusivity, clinical protocol assistance, waivers or reductions in regulatory fees. ALS was identified in 1869 by French neurologist Dr Jean-Martin Charcot. Today with about 500,000 patients worldwide with a high unmet medical need.   #NX210c #ODD #ALS #EMA #FDA #BBB Axoltis Pharma

📯 Axoltis Pharma's team is very proud to be among the #PrixGalien USA Award nominees for "Best Startup" !   This year marks the tenth anniversary of The Galien Foundation and Business France recognizing global innovators in the "Best Startup" category. This partnership supports global healthcare startups by offering visibility on the American stage and connecting them with major players in the industry in the U.S. and Canada. Axoltis aims to expand its current panel of collaborations with academic labs and with potential pharma partners in the world, especially in North America to explore the broad range of indications of its patented lead product #NX210c.   NX210c could change the game in the treatment of neurodegenerative diseases. Aside to a neuroprotective effect, its main property is the recovery of the blood brain barrier integrity which is impaired in a broad range of diseases. Axoltis has just launched a phase II clinical trial in Amyotrophic Lateral Sclerosis (#ALS), where the #BBB is impaired since the early stages of the disease. ALS is a fatal disease with a huge unmet medical need.. #PrixGalienUSA #BusinessFranceNorthAmerica #FrenchHealthcare #ChooseFrance